CN105748518B - Anti-apolexis composition comprising fat stem cell extract - Google Patents
Anti-apolexis composition comprising fat stem cell extract Download PDFInfo
- Publication number
- CN105748518B CN105748518B CN201610161141.0A CN201610161141A CN105748518B CN 105748518 B CN105748518 B CN 105748518B CN 201610161141 A CN201610161141 A CN 201610161141A CN 105748518 B CN105748518 B CN 105748518B
- Authority
- CN
- China
- Prior art keywords
- stem cell
- apolexis composition
- culture
- cell extract
- fat stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000006285 cell suspension Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 238000000197 pyrolysis Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000032683 aging Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- -1 P-hydroxybenzoic acid Methyl esters Chemical class 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 101710168454 Beta-galactosidase A Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100037241 Endoglin Human genes 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920003110 Primojel Polymers 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to field of medicaments, and in particular to a kind of anti-apolexis composition comprising fat stem cell extract.The fat stem cell carries out fat stem cell extraction after the slight damage of ultraviolet irradiation and A.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of anti-apolexis composition comprising fat stem cell extract.
Background technique
Aging is the biological process of too many levels, is body in the general performance of period function reduction and disorder of degenerating.It is general
It is the essential characteristic of human senility all over property, progressive, degeneration and endogenous.The research of Aging mechanism to the 1940s
Into physiology, biochemistry and form aspects systematic research.Many new theories are proposed on the basis of many experiments evidence,
Free radical theory, genetic program theory, cross linkage theory, lipofuscin accumulation theory, hypoendocrinism theory etc., respectively
The mechanism and countermeasure of aging generation have been inquired into from different angles.
Antiaging agent is a kind of to improve life efficiency as final purpose, is played from multisystem, multi-level and multistage
It adjusts function, delays senility or improve the drug of quality of life in the life time that can be defined on science of heredity.People carry out
It is a large amount of to explore, some experiences and effective method are had accumulated, some antiaging agents have also been developed.Such as ginkgo leaf extracts
Object, vitamin E and hormone etc., although there is many drugs to be all proved to be able to delay senescence at present, antiaging agent can not
It abuses, caused toxicity case is increasing.
Fat stem cell (Adipose-derived Stem Cells, ADSCs), is to be now widely used for organizational project
And a kind of adult stem cell of regenerative medicine research field.Fat stem cell has multidirectional point as mesenchymal stem cell
Change potential, under given conditions can to fat cell, osteoblast, chondroblast, sarcoblast, at endothelial cell and at
The differentiation of the multiple directions such as nerve cell.In addition to this, fat stem cell also has the ability for secreting various trophic factors,
These factors include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor
(VEGF), VEGF R2 (VEGFR2), Basic Fibroblast Growth Factor (bFGF) etc., these factors can also
To participate in the injury repair of histoorgan.
Summary of the invention
It is an object of the present invention to provide a kind of anti-apolexis composition comprising fat stem cell extract, the fat
Stem cell extract the preparation method is as follows:
1) 0.1% gelatin spreads T75 Tissue Culture Flask half an hour, blots and stands 5 minutes；
2) human adipose-derived stem cell is adjusted to 1 × 10 with serum free medium5The human adipose-derived stem cell suspension of a/ml；Culture
Addition 15ml suspension is cultivated in bottle, and serum free medium replaces (A β) containing amyloid beta after incubator culture three days
Serum free medium, culture bottle is irradiated using UV crosslinking instrument after changing liquid；
3) it is cultivated three days after irradiating；Culture solution is sucked out, is cleaned 2-3 times with PBS, then plus 2-3ml cell pyrolysis liquid dissolves
Then cell is collected into centrifuge tube, centrifuging and taking supernatant；
4) it takes supernatant to be placed in bag filter, is dialysed 8 hours with 4 DEG C of PBS solutions；Solution in bag filter is freeze-dried,
It is stored in -80 DEG C of refrigerators.
In one embodiment of the invention, the concentration of the amyloid beta is 0.1 μ g/L.
In another embodiment of the present invention, the UV crosslinking instrument is to the actual conditions that culture bottle is irradiated
With 1mJ/cm2Irradiate 10min.
In yet another embodiment of the present invention, the actual conditions of centrifugation described in step 3 are 12000rpm centrifugation
10min。
In yet another embodiment of the present invention, dialysis bag retention molecular weight described in step 4 is 5000kD.
It is further carried out in scheme in the present invention, the anti-apolexis composition is by the fat stem cell extract and two
The mass ratio of first biguanides composition, the fat stem cell extract and melbine is 10:0.3.
The anti-apolexis composition can be formulated for being administered orally, drug administration by injection, percutaneous dosing, be implanted into storage cavern or rectum
Administration, or for suitable for by sucking or by way of being blown into administration (by mouth or nose).
For oral administration, the anti-apolexis composition can take the form of such as tablet or capsule, the tablet or glue
Capsule is prepared with pharmaceutically acceptable excipients by conventional method, and the pharmaceutically acceptable excipients are for example to bond
Agent (for example, pregelatinized corn starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose)；Filler (for example, lactose,
Microcrystalline cellulose or calcium monohydrogen phosphate)；Lubricant (for example, magnesium stearate, talcum or silica)；Disintegrating agent is (for example, potato
Starch or primojel)；Or wetting agent (for example, NaLS).It can be by methods known in the art to described
Tablet is coated.The form of such as solution, syrup or suspending agent can be taken for the liquid preparation of oral administration, or
They can be provided by anhydrous Product Form for using preceding molten with water or other medium weights appropriate.Such liquid preparation
It can be prepared by conventional method with pharmaceutically acceptable additive, the pharmaceutically acceptable additive is such as suspending agent
(for example, sorbitol syrups, cellulose derivative or hydrogenated edible lipid)；Emulsifier (for example, lecithin or Arabic gum)；
Non-aqueous vehicles (for example, apricot kernel oil, oily ester, ethyl alcohol or fractionated vegetable oil)；With preservative (for example, P-hydroxybenzoic acid
Methyl esters or propylparaben or sorbic acid).The preparation can also contain buffer salt, corrigent, colorant as needed
And sweetener.Formulations for oral administration can be through preparation appropriate, to provide the control release of reactive compound.
The anti-apolexis composition can be formulated for percutaneous dosing.Percutaneous dosing may include topical application or it is transdermal to
Medicine.Transdermal application can by patch appropriate, emulsion, ointment, solution, suspending agent, paste, foaming agent, aerosol, wash
Agent, cream or gelling agent are completed, and are commonly known in the art, and are specially designed to transdermal delivery activity
Agent, and optionally in the presence of specific penetration enhancer.Topical composition can equally take one of these forms or a variety of.
One or more reactive compounds can combine presence with one or more pharmaceutically acceptable non-toxic excipients, and as needed
Combine presence, the pharmaceutically acceptable auxiliary material, such as excipients, auxiliary agent (for example, buffer), load with other active components
Body, inert solid diluent, suspending agent, preservative, filler, stabilizer, antioxidant, food additives, bioavilability
Reinforcing agent, coating substance, granulation agent and disintegrating agent, adhesive etc..
In the present invention, the human adipose-derived stem cell refers to people adipose stromal stem cell, can be bought by commercial channel
It obtains, can also voluntarily be prepared by method known in the art, such as preparation method disclosed in patent CN2014103601433
(its specification embodiment 1) is prepared, as long as the fat stem cell obtained is detected through antigen, has CD34, CD31 and CD45
The total stem cell ratio of fat stem cell Zhan be lower than 1%；Fat stem cell with CD29, CD73, CD90, CD105 and CD49d
It is higher than 95% in the ratio of total stem cell.
Present invention discover that the defense mechanism inside stem cell can be activated under the slight damage of ultraviolet irradiation and A β, from
And it is made largely to secrete beneficial growth factor and related substances, so that the activity of fighting against senium of stem cell be made to greatly improve.In addition,
In further research, present invention discover that the fat stem cell extract is produced with melbine significantly cooperates with work
With；To make drug effect greatly improve.
Specific embodiment
Below by further the present invention will be described in detail.It should be pointed out that following explanation be only to the present invention claims
The technical solution of protection for example, not to any restrictions of these technical solutions.Protection scope of the present invention is with appended
Subject to the content that claims are recorded.
The preparation of 1 fat stem cell extract of embodiment
1) 0.1% gelatin spreads T75 Tissue Culture Flask half an hour, blots and stands 5 minutes；
2) by human adipose-derived stem cell serum free medium (modelMSC SFM, Thermo Fisher are public
Department, the U.S., similarly hereinafter) it is adjusted to 1 × 105The human adipose-derived stem cell suspension of a/ml；15ml suspension is added in culture bottle to be cultivated,
The serum free medium of amyloid beta (A β) of the serum free medium replacement containing 0.1 μ g/L, is changed after incubator culture three days
Culture bottle is irradiated using UV crosslinking instrument after liquid；Condition is with 1mJ/cm2Irradiate 10min.
3) it is cultivated three days after irradiating；Culture solution is sucked out, is cleaned 2-3 times with PBS, then plus 2-3ml cell pyrolysis liquid dissolves
Then cell is collected into centrifuge tube, 12000rpm is centrifuged 10min, takes supernatant；
4) it takes supernatant to be placed in bag filter (molecular cut off 5000kD), is dialysed 8 hours with 4 DEG C of PBS solutions；It will be saturating
Solution freeze-drying in bag is analysed, -80 DEG C of refrigerators are stored in.
2 D- galactolipin of embodiment causes the research of senile cell model
Take H9C2 cardiac muscle cell, PC12 nerve cell and human fibroblasts HDF respectively with 1 × 105A/ml is laid on difference
96 orifice plates, after incubator culture 3 days, the culture medium that fatty stem cell extract and D- galactolipin is added is incubated for；Every hole D-
The final concentration of 30mg/ml of galactolipin；Control group does not add galactolipin and drug, and model group adds galactolipin but do not add medicine
Object after cultivating 48h, measures cell activity using mtt assay, and using (every group 5 of content of FDG method detection beta galactosidase
A multiple holes, parallel testing 3 times).
Concrete outcome is as shown in the table:
| OD590 | Concentration | H9C2 | PC12 | HDF |
| Control group | - | 0.77±0.03 | 0.56±0.02 | 0.84±0.04 |
| Model group | - | 0.52±0.02 | 0.31±0.01 | 0.61±0.03 |
| Embodiment 1 | 10μg/L | 0.69±0.03 | 0.48±0.02 | 0.76±0.03 |
| 30μg/L | 0.78±0.03 | 0.54±0.03 | 0.83±0.04 | |
| Comparative example 1 | 10μg/L | 0.58±0.02 | 0.37±0.01 | 0.68±0.02 |
| 30μg/L | 0.62±0.03 | 0.45±0.02 | 0.74±0.03 | |
| Comparative example 2 | 10μg/L | 0.60±0.03 | 0.41±0.03 | 0.71±0.03 |
| 30μg/L | 0.67±0.03 | 0.47±0.03 | 0.78±0.02 |
| Beta galactosidase | Concentration | H9C2 | PC12 | HDF |
| Control group | - | 1764±87 | 892±42 | 1344±98 |
| Model group | - | 7942±274 | 4672±148 | 6109±176 |
| Embodiment 1 | 10μg/L | 2542±119 | 1614±94 | 1952±83 |
| 30μg/L | 1913±94 | 1035±75 | 1479±71 | |
| Comparative example 1 | 10μg/L | 5274±189 | 3352±121 | 4743±194 |
| 30μg/L | 3751±157 | 2514±108 | 2719±164 | |
| Comparative example 2 | 10μg/L | 4359±172 | 2845±147 | 3259±176 |
| 30μg/L | 3039±147 | 1861±113 | 2152±132 |
Comparative example 1 be fat stem cell extract, the preparation method is the same as that of Example 1, difference be only that fat stem cell without
Ultraviolet irradiation and A β processing；
Comparative example 2 is fat stem cell extract, and the preparation method is the same as that of Example 1, and difference is only that fat stem cell without A
β processing.
The research of 3 SAM aging mice model of embodiment
It takes Senescence-Accelerated Mouse SAM-P/8 (3 monthly age), half male and half female, random to be grouped, every group of 15-20 is only, each to be administered
Group carries out gastric infusion according to dosage 5mg/kg, and control group gives same amount of normal saline, and daily stomach-filling is once until examination
End is tested, normal condition raising counts each group mouse life and the death rate and carries out to survival mice following after raising 10 months
Test:
1) water maze is tested: mouse being put into the round pool containing circular platform, depth of water 30cm, if mouse is more than
60s can not find platform, and mouse is put into platform by experimenter and is familiar with environment 10s, after continuous training 3 days, records every mouse and looks for
To plateau time.
2) proliferation of bone marrow cells ability measures: it is sterile to take mouse bilateral femur upper segment, after being rinsed with Hanks liquid, cut off two
End, 1640 flush out bone marrow cell, and centrifugation obtains cell, with 1640 culture keynote cell concentrations to 1 × 106A/ml, every hole
100 microlitres are seeded to 96 orifice plates, cultivate 3 days, using the OD value of mtt assay measurement 590nm.
3) index and spleen index and thymus index measurement: taking mouse spleen and thymus gland, weigh, calculate spleen and thymic weight with it is small
The ratio of mouse weight.
Concrete outcome is as follows:
1, the average life span of each group mouse and the death rate after raising 10 months
| The death rate (%) | Average life span (day) | |
| Control group | 51.3 | 127.5 |
| Embodiment 1 | 5.2 | 269.6 |
| Comparative example 1 | 21.9 | 184.3 |
| Comparative example 2 | 14.3 | 224.9 |
| Test example 1 | 1.3 | 292.6 |
The comparative example 1 and 2 that the administration medicine of comparative example 1 and 2 is prepared referring to embodiment 3；
Test example 1 is the composition of fat stem cell extract prepared by embodiment 1 and melbine, and the two is mixed,
The weight ratio of fat stem cell extract and melbine is 10:0.3.
2, water maze
| Incubation period (s) | |
| Control group | 61.9±6.7 |
| Embodiment 1 | 30.9±4.8 |
| Comparative example 1 | 49.5±4.2 |
| Comparative example 2 | 40.3±3.9 |
| Test example 1 | 25.2±4.4 |
3, proliferation of bone marrow cells ability
| OD value | |
| Control group | 0.24±0.05 |
| Embodiment 1 | 0.41±0.04 |
| Comparative example 1 | 0.29±0.05 |
| Comparative example 2 | 0.32±0.04 |
| Test example 1 | 0.54±0.06 |
4, index and spleen index and thymus index
| Index and spleen index (mg/g) | Thymus index (mg/g) | |
| Control group | 3.9±0.7 | 1.7±0.3 |
| Embodiment 1 | 5.7±1.1 | 2.8±0.5 |
| Comparative example 1 | 4.4±0.6 | 1.9±0.4 |
| Comparative example 2 | 4.8±0.5 | 2.2±0.4 |
| Test example 1 | 6.1±1.2 | 3.2±0.6 |
The content of present invention merely illustrates claimed some specific embodiments, one of them or more skill
Documented technical characteristic can be combined with arbitrary one or more technical solutions in art scheme, these are combined and obtain
Technical solution also in the application protection scope, the technical solution just as obtained from these are combined is disclosed in the present invention
It is specifically recorded in content the same.
Claims (5)
1. a kind of anti-apolexis composition comprising fat stem cell extract, the preparation method of the fat stem cell extract is such as
Under:
1) 0.1% gelatin spreads T75 Tissue Culture Flask half an hour, blots and stands 5 minutes；
2) human adipose-derived stem cell is adjusted to 1 × 10 with serum free medium5The human adipose-derived stem cell suspension of a/ml；Add in culture bottle
15ml suspension is added to be cultivated, serum free medium replacement is containing amyloid beta (A β) without blood after incubator culture three days
Clear culture medium is irradiated culture bottle using UV crosslinking instrument after changing liquid；The concentration of the amyloid beta is 0.1 μ g/L；
The UV crosslinking instrument is with 1mJ/cm to the actual conditions that culture bottle is irradiated2Irradiate 10min；
3) it is cultivated three days after irradiating；Culture solution is sucked out, is cleaned 2-3 times with PBS, then plus 2-3ml cell pyrolysis liquid dissolves cell,
Then it is collected into centrifuge tube, centrifuging and taking supernatant；
4) it takes supernatant to be placed in bag filter, is dialysed 8 hours with 4 DEG C of PBS solutions；Solution in bag filter is freeze-dried, is saved
In -80 DEG C of refrigerators.
2. anti-apolexis composition according to claim 1, which is characterized in that the actual conditions of centrifugation described in step 3 are
12000rpm is centrifuged 10min.
3. anti-apolexis composition according to claim 1, which is characterized in that dialysis bag retention molecular weight described in step 4
For 5000kD.
4. anti-apolexis composition according to claim 1, which is characterized in that the anti-apolexis composition is dry by the fat
Cell extract and melbine composition.
5. anti-apolexis composition according to claim 4, which is characterized in that the fat stem cell extract and diformazan are double
The mass ratio of guanidine is 10:0.3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610161141.0A CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610161141.0A CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105748518A CN105748518A (en) | 2016-07-13 |
| CN105748518B true CN105748518B (en) | 2019-06-07 |
Family
ID=56345394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610161141.0A Active CN105748518B (en) | 2016-03-21 | 2016-03-21 | Anti-apolexis composition comprising fat stem cell extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105748518B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11065188B2 (en) | 2019-05-29 | 2021-07-20 | Av Laboratories Llc | Applications and formulations of optimized, modified human embryonic fertility culture media with biguanides and/or functional equivalents |
| CN114288202A (en) * | 2021-12-06 | 2022-04-08 | 广州沛妍医疗科技有限公司 | A sericin composition with antiaging effect, and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101400787A (en) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | Mass producing method of growth factor using adipose derived adult stem cells |
| CN101652063A (en) * | 2007-02-06 | 2010-02-17 | T·J·杨 | Use gene therapy treatment and prevention neurodegenerative disease |
| CN104224841A (en) * | 2014-09-13 | 2014-12-24 | 黑龙江天晴干细胞有限公司 | Method for preparing stem cell preparation |
| CN104762260A (en) * | 2015-04-23 | 2015-07-08 | 广州赛莱拉干细胞科技股份有限公司 | Preparation method and application of adipose-derived mesenchymal stem cells and preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120105948A (en) * | 2011-03-17 | 2012-09-26 | (주)프로스테믹스 | Enriched media of human adipose tissue-derived stem cells having regeneration effects of ectodermal origin cells and uses thereof |
-
2016
- 2016-03-21 CN CN201610161141.0A patent/CN105748518B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101400787A (en) * | 2006-01-27 | 2009-04-01 | 株式会社Prostemics | Mass producing method of growth factor using adipose derived adult stem cells |
| CN101652063A (en) * | 2007-02-06 | 2010-02-17 | T·J·杨 | Use gene therapy treatment and prevention neurodegenerative disease |
| CN104224841A (en) * | 2014-09-13 | 2014-12-24 | 黑龙江天晴干细胞有限公司 | Method for preparing stem cell preparation |
| CN104762260A (en) * | 2015-04-23 | 2015-07-08 | 广州赛莱拉干细胞科技股份有限公司 | Preparation method and application of adipose-derived mesenchymal stem cells and preparation thereof |
Non-Patent Citations (3)
| Title |
|---|
| Ultraviolet A Regulates the Stemness of Human Adipose Tissue-Derived Mesenchymal Stem Cells Through Downregulation of the HIF-1a via Activation of PGE2–cAMP Signaling;Jongsung Lee et al.;《Journal of Cellular Biochemistry》;20120702;第113卷;第3681-3691页 |
| β-淀粉样蛋白对体外培养的神经干细胞作用研究;胥显民等;《中国病理生理杂志》;20051231;第21卷(第1期);第139-142页 |
| 脂肪来源干细胞相关生长因子及其作用的研究进展;赵珮娟等;《组织工程与重建外科杂志》;20131031;第9卷(第5期);第285-288页 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105748518A (en) | 2016-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brini et al. | Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel | |
| Wu et al. | Optimization of Glycyrrhiza polysaccharide liposome by response surface methodology and its immune activities | |
| CN103327992B (en) | For prevent or treat inflammatory diseases comprise Caulis Trachelospermi extract and the pharmaceutical composition of Cortex Moutan extract and the method preparing this pharmaceutical composition | |
| KR101742629B1 (en) | Cosmetic composition for promoting the stemness of adipose-derived stem cell containing apple stem cell extracts | |
| De Siena et al. | Omentum-derived stromal cells improve myocardial regeneration in pig post-infarcted heart through a potent paracrine mechanism | |
| Chen et al. | Timing of transplantation of autologous bone marrow derived mesenchymal stem cells for treating myocardial infarction | |
| CN105748518B (en) | Anti-apolexis composition comprising fat stem cell extract | |
| Ude et al. | Stromal vascular fraction for osteoarthritis of the knee regenerative engineering | |
| JPWO2013136871A1 (en) | Persulfated chondroitin composition | |
| Cong et al. | Current and novel therapeutics for articular cartilage repair and regeneration | |
| KR101565856B1 (en) | Composition for promoting osteogenic differentiation of human mesenchymal stem cells comprising cortex mori radicis extract, patrinia saniculaefolia extract or mixture thereof | |
| AU2018220880B2 (en) | Composition for cough | |
| CN103040910A (en) | Cervus and cucumis polypeptide liposome injection | |
| CN108904533A (en) | Dental pulp mescenchymal stem cell is preparing the purposes in cirrhosis treatment drug | |
| CN109864964B (en) | Anti-aging composition containing stem cells and application thereof | |
| CN107427546A (en) | Composition and its medicinal application containing interwined dragon conopsea extraction | |
| CN109771411A (en) | Dihydroquercetin is used to prepare the purposes in the drug for the treatment of fatty liver | |
| He et al. | Black phosphorus quantum dot-modified ADSCs as a novel therapeutic for periodontitis bone loss coupling of osteogenesis and osteoimmunomodulation | |
| CN105030777B (en) | Enhancing ALK TKI curative effects, the compound and its preparation for delaying its resistance | |
| CN104490802B (en) | Rhodioside enteric coatel tablets and preparation method thereof | |
| US7387781B2 (en) | Agents for treating osteoporosis and inhibiting osteoclast formation | |
| CN107468708A (en) | A kind of preparation method of Stem Cell Activity factor gel and the application in Hard agglut wound treatment | |
| KR20120058864A (en) | Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing bifidobacteria extracts | |
| KR101529493B1 (en) | Perillae semen extracts for enhancing differentiation of osteoblast and inhibiting differentiation of osteoclast and use of thereof as bone formation promoting products and bone resorption inhibitory products | |
| Park et al. | Trichostatin A enhances osteogenic differentiation through activation of ERK pathways in mouse bone marrow multipotent stromal cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160713 Assignee: ZHEN-AO GROUP Co.,Ltd. Assignor: DALIAN University Contract record no.: X2023210000229 Denomination of invention: Anti aging composition containing adipose stem cell extract Granted publication date: 20190607 License type: Common License Record date: 20231129 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20160713 Assignee: Dalian Xinzerui Technology Co.,Ltd. Assignor: DALIAN University Contract record no.: X2023210000261 Denomination of invention: Anti aging composition containing adipose stem cell extract Granted publication date: 20190607 License type: Common License Record date: 20231130 |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240208 Address after: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee after: Chengdu yishenrui Technology Co.,Ltd. Country or region after: China Address before: 116622 No. 10 Xuefu street, Jinzhou New District, Dalian, Liaoning. Patentee before: DALIAN University Country or region before: China |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240223 Address after: Room 201, Unit 1, Building 5, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100000 Patentee after: Beijing Jiamei Kanglian Medical Technology Co.,Ltd. Country or region after: China Address before: No.13, 3rd floor, building 1, No.1, Tidu street, Qingyang District, Chengdu, Sichuan 610000 Patentee before: Chengdu yishenrui Technology Co.,Ltd. Country or region before: China |
|
| TR01 | Transfer of patent right |